BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Large Growth in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the target of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 688,400 shares, an increase of 28.7% from the November 15th total of 534,800 shares. Based on an average daily volume of 5,250,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.1% of the shares of the stock are sold short.

Institutional Investors Weigh In On BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned about 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. Institutional investors own 15.42% of the company’s stock.

BriaCell Therapeutics Stock Performance

Shares of BriaCell Therapeutics stock remained flat at $0.66 during trading on Friday. 2,202,279 shares of the stock traded hands, compared to its average volume of 1,642,969. The stock has a market capitalization of $23.88 million, a price-to-earnings ratio of -0.56 and a beta of 1.46. BriaCell Therapeutics has a 52-week low of $0.46 and a 52-week high of $5.97. The company’s 50 day moving average price is $0.84 and its 200-day moving average price is $0.89.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.45. On average, sell-side analysts expect that BriaCell Therapeutics will post -1.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of BriaCell Therapeutics in a research report on Thursday.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.